



Company Contact:
Jie Du, Ph.D.
President & CEO
JDP THERAPEUTICS, INC.
Email: jiedu@jdptherapeutics.com
www.jdptherapeutics.com

First Patient Enrolled in Initial Phase III Study of JDP-205 Injection for the Treatment of Acute Urticaria

ETTAU Study Enrolling Patients to Evaluate Efficacy, Safety, and Tolerability of JDP-205

BLUE BELL, PENNSYLVANIA, July 12, 2013 – JDP Therapeutics Inc., a privately held clinical stage specialty pharmaceutical company, announced enrollment of the first patient in the ETTAU-02 study (Efficacy Trial of JDP-205 for the Treatment of Acute Urticaria), a pilot Phase III clinical trial. It is a multi-sites, randomized, double-blind study designed to evaluate the efficacy, safety and tolerability of JDP-205 Injection in patients with Acute Urticaria. The outcome measure of ETTAU-02 will be to confirm the efficacy as measured by the acute urticaria symptom reduction scores. To optimize the study process, the enrollment sites include emergency departments, allergy clinics, and urgent care centers.

Previous studies have shown that JDP-205 is safe and provides an immediate onset of action in human volunteers. The quick onset is required for acute allergic reactions (acute urticaria) - an acute disease condition. Studies conducted by independent investigators in published literatures also demonstrated that the oral version of the same molecule provided as great efficacy as the current therapy with much less side effects. “We are currently enrolling patients in this initial phase III clinical trial to evaluate the efficacy and side effects (safety and tolerability) of JDP-205 Injection on acute urticaria patients. It is exciting to see that the 1st patient has been enrolled”, said ETTAU’s investigator, Dr. Gordon Sussman, from Toronto, Canada. Another phase III trial with a larger number of patients has also been planned.

About JDP-205

JDP-205 is a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market. A market QUANT study surveyed 110 physicians, and revealed that 86% of responding doctors had indicated readiness to use JDP-205 in place of the current therapy when the product is approved by the FDA. A second independent market research study with in-depth clinician interviews confirmed the findings.

Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates with very limited selections of medications for treatment. JDP-205 will offer an alternative and superior treatment to the current therapy for the first time in nearly 60 years.

About JDP Therapeutics Inc.

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email info@jdptherapeutics.com

###

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical fact, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.